Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18003544 | 0.83 | ALOX5 (0.42) | KDM4EALDH1A1MEN1LMNAMAPT | |
| SCHEMBL8989145 | 0.81 | KDM4E (0.44) | TDP2KDM4EALDH1A1MEN1LMNA | |
| SCHEMBL8989227 | 0.81 | ALDH1A1 (0.41) | TDP2KDM4EALDH1A1MEN1LMNA | |
| SCHEMBL18003191 | 0.80 | ALDH1A1 (0.54) | TDP2KDM4EALDH1A1MEN1LMNA | |
| SCHEMBL9143201 | 0.79 | SIGMAR1 (0.43) | TDP2KDM4EALDH1A1LMNACTSS | |
| SCHEMBL8989194 | 0.79 | ADORA2B (0.44) | TDP2KDM4EALDH1A1MEN1LMNA | |
| SCHEMBL18003589 | 0.79 | KDM4E (0.42) | TDP2KDM4EALDH1A1SIGMAR1PTGS2 | |
| SCHEMBL8989105 | 0.77 | KDM4E (0.41) | TDP2KDM4EALDH1A1MEN1LMNA | |
| SCHEMBL8989243 | 0.77 | PARP1 (0.44) | KDM4EALDH1A1MEN1LMNAMAPT | |
| SCHEMBL6652679 | 0.76 | CFTR (0.52) | KDM4EALDH1A1MEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-5545645-A | Heterocyclic derivatives in the treatment of ischaemia and related diseases | SYNTEX PHARMACEUTICALS, LIMITED (GB) | 1996-08-13 | — | — | US | disclosed |
| US-5428037-A | Piperazine derivatives; calcium and sodium channel antagonists | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1995-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | TDP2 2933/4885KDM4E 2681/4885ALDH1A1 1611/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | TDP2 2933/4885KDM4E 2681/4885ALDH1A1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.